Skip to main content

Revance Therapeutics, Inc.

RVNCDelisted Feb 6, 2025
Industry
Pharmaceutical Preparations
SEC CIK
0001479290

Revance Therapeutics, Inc. was delisted on Feb 6, 2025; its insiders filed their last Form 4 on Feb 6, 2025; 174 institutions reported holding it in 13F filings for Q4 2024, worth $249.2M in total; Fairfax Financial was the only superinvestor holding it.

13F holders, Q2 2025

Institutional positions in Revance Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

RVNC is no longer listed, and 13F filings after Q4 2024 list far fewer holders. See Q4 2024

Institutional holders
0
−2 vs. Q1 2025
Shares held
0
−86.1K (−100.0%) vs. Q1 2025
Total value
$0
−$425.0K (−100.0%) vs. Q1 2025
New holders
0
0 more added
Sold out
2
0 more reduced

Compare with Q1 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting RVNC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2025: 0 institutions
Q1 2021: 149 institutionsQ2 2021: 161 institutionsQ3 2021: 159 institutionsQ4 2021: 151 institutionsQ1 2022: 156 institutionsQ2 2022: 161 institutionsQ3 2022: 182 institutionsQ4 2022: 193 institutionsQ1 2023: 217 institutionsQ2 2023: 215 institutionsQ3 2023: 187 institutionsQ4 2023: 193 institutionsQ1 2024: 188 institutionsQ2 2024: 173 institutionsQ3 2024: 201 institutionsQ4 2024: 174 institutionsQ1 2025: 2 institutionsQ2 2025: 0 institutionsQ3 2025: 0 institutionsQ4 2025: 0 institutionsQ1 2026: 0 institutionsQ2 2026: 0 institutions
Value heldQ2 2025: $0
Q1 2021: $1.53BQ2 2021: $1.60BQ3 2021: $1.53BQ4 2021: $864.7MQ1 2022: $1.06BQ2 2022: $774.3MQ3 2022: $1.82BQ4 2022: $1.36BQ1 2023: $2.46BQ2 2023: $2.07BQ3 2023: $893.1MQ4 2023: $636.4MQ1 2024: $409.4MQ2 2024: $209.3MQ3 2024: $429.9MQ4 2024: $249.2MQ1 2025: $425.0KQ2 2025: $0Q3 2025: $0Q4 2025: $0Q1 2026: $0Q2 2026: $0
Institutions holding RVNC and their total value by quarter
QuarterHoldersValue
Q2 20260$0
Q1 20260$0
Q4 20250$0
Q3 20250$0
Q2 20250$0
Q1 20252$425.0K
Q4 2024174$249.2M
Q3 2024201$429.9M
Q2 2024173$209.3M
Q1 2024188$409.4M
Q4 2023193$636.4M
Q3 2023187$893.1M
Q2 2023215$2.07B
Q1 2023217$2.46B
Q4 2022193$1.36B
Q3 2022182$1.82B
Q2 2022161$774.3M
Q1 2022156$1.06B
Q4 2021151$864.7M
Q3 2021159$1.53B
Q2 2021161$1.60B
Q1 2021149$1.53B

Institutions, Q2 2025

Shares, value and share of portfolio for each institution holding Revance Therapeutics, Inc.; share changes are against Q1 2025.

Institutions holding RVNC in Q2 2025
InstitutionSharesValue% of portfolioChange in sharesAction
DekaBank Deutsche Girozentrale0$00.00%−86,100−100.0%Sold out
IFP Advisors, Inc0$00.00%0Sold out